LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma

DOI: https://doi.org/10.1186/s12885-023-10594-y
IF: 4.638
2023-02-07
BMC Cancer
Abstract:Glioma is characterized by high morbidity, high mortality, and poor prognosis. Despite tremendous advances in the treatment of glioma, the prognosis of patients with glioma is still unsatisfactory. There is an urgent need to discover novel molecular markers that effectively predict prognosis in patients with glioma. The investigation of the role of WEE2-AS1 in various tumors is an emerging research field, but the biological function and prognostic value of WEE2-AS1 in glioma have rarely been reported. This study aimed to assess the value of WEE2-AS1 as a potential prognostic marker of glioma.
oncology
What problem does this paper attempt to address?